Langerhans cell histiocytosis (LCH) is a rare and clinically heterogeneous hematological
disease characterized by the accumulation of mononuclear phagocytes in various tissues …

The mitogen-activated protein kinase (MAPK) pathway is a key driver in many histiocytic
disorders, including Langerhans cell histiocytosis (LCH) and Erdheim–Chester disease …

Langerhans cell histiocytosis (LCH) is a potentially fatal neoplasm characterized by the
aberrant differentiation of mononuclear phagocytes, driven by mitogen-activated protein …

Background Intratumoral regulatory T cells (Treg) in colon cancer are a heterogeneous cell
population, with potential impact on patient outcome. Generally, a high Treg infiltration has …

Langerhans cell histiocytosis (LCH) is an inflammatory myeloid malignancy in the “L-group”
histiocytosis. Mitogen-activated protein kinase (MAPK) pathway activating mutations are …

Altered intestinal immune homeostasis leads to chronic inflammation in Crohn's disease
(CD). To address disease-and tissue-specific alterations, we performed a T cell-centric mass …

Background and aim Preeclampsia (PE), a multifactorial disorder, is the main cause of
maternal mortality and morbidity. Genetic polymorphisms in key proteins involved in the …

The inflammation/immune response pathway is considered a key contributor to the
development of Langerhans cell histiocytosis (LCH) bone metastasis. However, the dynamic …

Langerhans cell histiocytosis (LCH) is characterised by lesions containing LCH cells, which
are myeloid-derived dendritic cells that coexpress CD1a and CD207 (langerin). In addition …

Although described in the 70's, CD8+ regulatory T cells (Tregs) remain incompletely
understood and to date, although several markers are used to define them, they remain …